# Combination of Temsirolimus and Bevacizumab in Patient With Metastatic Renal Cell Carcinoma

> **NCT00619268** · PHASE2 · COMPLETED · sponsor: **Centre Leon Berard** · enrollment: 160 (estimated)

## Conditions studied

- Metastatic Renal Cell Carcinoma

## Interventions

- **DRUG:** Temsirolimus
- **DRUG:** Bevacizumab
- **DRUG:** Sunitinib
- **DRUG:** Interferon alpha-2a

## Key facts

- **NCT ID:** NCT00619268
- **Lead sponsor:** Centre Leon Berard
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-02
- **Primary completion:** 2012-02
- **Final completion:** 2012-02
- **Target enrollment:** 160 (ESTIMATED)
- **Last updated:** 2013-02-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00619268

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00619268, "Combination of Temsirolimus and Bevacizumab in Patient With Metastatic Renal Cell Carcinoma". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT00619268. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*